These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20447706)

  • 1. Multivalent antibodies: when design surpasses evolution.
    Cuesta AM; Sainz-Pastor N; Bonet J; Oliva B; Alvarez-Vallina L
    Trends Biotechnol; 2010 Jul; 28(7):355-62. PubMed ID: 20447706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
    Deyev SM; Lebedenko EN
    Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabodies: molecular engineering and therapeutic applications.
    Wu C
    Drug News Perspect; 2009 Oct; 22(8):453-8. PubMed ID: 20016854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors.
    Beckman RA; Weiner LM; Davis HM
    Cancer; 2007 Jan; 109(2):170-9. PubMed ID: 17154393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in biomolecular engineering.
    Ryu DD; Nam DH
    Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered affinity proteins for tumour-targeting applications.
    Friedman M; Ståhl S
    Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoconjugates against solid tumors: mind the gap.
    Ricart AD
    Clin Pharmacol Ther; 2011 Apr; 89(4):513-23. PubMed ID: 21368753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant antibodies: alternative strategies for developing and manipulating murine-derived monoclonal antibodies.
    Peterson NC
    Lab Anim Sci; 1996 Feb; 46(1):8-14. PubMed ID: 8699826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal and recombinant antibodies, 30 years after ..
    Laffly E; Sodoyer R
    Hum Antibodies; 2005; 14(1-2):33-55. PubMed ID: 16424599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved tumor targeting by combined use of two antitenascin antibodies.
    Petronzelli F; Pelliccia A; Anastasi AM; D'Alessio V; Albertoni C; Rosi A; Leoni B; De Angelis C; Paganelli G; Palombo G; Dani M; Carminati P; De Santis R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7137s-7145s. PubMed ID: 16203813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Directed evolution for drug and nucleic acid delivery.
    Hida K; Hanes J; Ostermeier M
    Adv Drug Deliv Rev; 2007 Dec; 59(15):1562-78. PubMed ID: 17933418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creating the next generation of protein therapeutics through rational drug design.
    Szymkowski DE
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):590-600. PubMed ID: 16159021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
    Ojima I
    Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies in the therapy of colon cancer.
    Welt S; Ritter G
    Semin Oncol; 1999 Dec; 26(6):683-90. PubMed ID: 10606261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.